FDA Eyeing More Proactive Role In Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will seek legislation allowing it to initiate meetings with industry on drug targets, Acting Commissioner Crawford says. FDA will make available to industry drug target opportunities and "actively engage" in drug programs.
You may also be interested in...
Obesity Drug Development On Tap For Advisory Committee Meeting In Fall
FDA's Metabolic & Endocrine and Food Advisory Committees are slated to discuss the agency's obesity treatment initiatives at a joint September meeting, Acting Commissioner Lester Crawford said at the World Obesity Congress in Washington, D.C. July 12
McClellan, Crawford On "Critical Path" To Secure Congress' Support For Drug Development Project
FDA Acting Commissioner Crawford tells FDLI conference that FDA "absolutely must" work with Congress to broaden support for new initiatives. FDA will enlist the help of CMS Administrator McClellan.
FDA To Create List Of Drug Development Obstacles
Roadblocks on the "critical path to new products" will be identified for safety assessment, evaluation of medical utility and product industrialization. FDA’s Science Board will meet in April to discuss the issue.